Mylan Laboratories (MYL) Receives FDA Approval for Generic Zoloft
More News related to MYL
- Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
- PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
- Mylan (MYL) Announces Exclusive Collaboration with Biocon to Enter Global Generic Biologics Market
- Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
- FTN Equity Starts Mylan Labs (MYL) at Neutral
More News related to PFE
- Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
- Pfizer Invites Public to Listen to Teleconference on Important Update Related to Chantix (R) (varenicline)
- Pfizer Inc (PFE) Updates U.S. Product Labeling for CHANTIX
- Pfizer Updates CHANTIX (R) (varenicline) Labeling in the United States
- Pfizer Launches Medicine Assistance Program for Newly Unemployed
More News related to FDA
- CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
- Lilly (LLY) Receives Fourth FDA Approval for ALIMTA
- Protalix (PLX) Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD
- ATS Medical (ATSI) Announces FDA Clearance of New ATS Simulus Semi-Rigid Annuloplasty Band
Mylan Laboratories Inc. (NYSE: MYL) announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Tablets, 25mg, 50mg and 100mg.
Sertraline Hydrochloride Tablets are the generic version of Pfizer's Zoloft (NYSE: PFE), which had U.S. sales of approximately $2.9 billion for the same strengths in the 12-month period ending Dec. 31, 2006, according to IMS Health.
Related Categories
FDAStocks Mentioned
-0.38
+12.58Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
